Pharmacy Pricing: Regulations, Margins, and Competition
In pharmacies, a large portion of the product lineup (reimbursable medications) has a price set by agreement with the CEPS, not by the retail outlet (Art. L162-16-4 CSS). The average gross margin for a pharmacy fell from 29.4% (2023) to 28.3% (2024, USPO). The only real area for pricing flexibility remains over-the-counter products, with margins ranging from 30% to 60%. ⚠️ Regulatory framework subject to change; please verify with official sources prior to publication.
The pharmacy sector is the retail sector where the first question regarding pricing is not “what price should I set,” but “do I even have control over this price?” A large portion of the pharmacy product lineup (reimbursable medications) is structurally beyond the control of the retail outlet’s commercial decisions.
This guide carefully establishes this framework, drawing on official sources, before addressing what truly constitutes a business decision at the pharmacy.
A two-tiered catalog—even before we get into the methodology
Before applying any pricing method to a pharmacy, it is necessary to make a fundamental distinction: part of the product catalog has a price that is regulated from start to finish, while another part has a completely unregulated price. Reimbursable medications have a retail price determined by a regulated mechanism: a manufacturer’s price negotiated with the CEPS, a distribution margin set by administrative order, and fixed dispensing fees. Non-reimbursable medications and over-the-counter products, on the other hand, have prices set freely.
How Is the Price of a Reimbursable Drug Determined?
Legal framework; to be verified on a case-by-case basis depending on the product. According to Article L162-16-4 of the Social Security Code, the retail price of each reimbursable medication is set by agreement between the company marketing the medication and the Economic Committee for Health Products (CEPS), or, in the absence of an agreement, by a decision of the committee or by an order issued by the relevant ministers (Légifrance).
According to the Leem, the CEPS’s mission is to “set the price of reimbursable drugs at the most advantageous level possible for the community of social security beneficiaries.” The retail price is then supplemented by a degressive distribution margin regulated by ministerial order, as well as a fixed dispensing fee paid to the pharmacist regardless of the price of the package (introduced in 2016). This mechanism results, with few exceptions, in a single retail price nationwide: it is not a variable that the point of sale adjusts for commercial purposes.
The Economic Reality of the Pharmacy: Margins Under Pressure
28.3% is the average overall gross margin for a French pharmacy in 2024 (as a percentage of pre-tax revenue), compared to 29.4% in 2023—a continued decline despite revenue growth (USPO, 2025 Economic Analysis). This paradox can be explained in large part by the structure of the list of reimbursable drugs: a growing share of revenue comes from expensive drugs, which have a lower regulated “ Markup ” due to the degressive nature of the margin scale.
290 pharmacies closed in France in 2024, compared with 197 in 2019, a sign of structural economic pressure on the independent pharmacy model (same source).
The drugstore: the only real arena for pricing decisions
For non-reimbursable medications and all over-the-counter products (cosmetics, personal care items, dietary supplements), prices are set freely, just as they are in any specialty store.
30–60% (this is the margin range generally observed for over-the-counter products, which are unregulated) compared to a significantly lower regulated margin on reimbursable products, particularly for expensive medications, where it is around 5% (industry sources from the pharmacy sector, 2024–2025). Over-the-counter products account for approximately 30 to 40% of a high-performing pharmacy’s revenue, but a significantly higher share of its total gross margin.
At Booper, humans are in control—there’s no “full-auto” mode: it’s not about applying a one-size-fits-all algorithmic pricing strategy across the entire catalog, but rather focusing pricing analysis and management where a business decision actually makes a difference. The price diagnostic Booper helps identify this actionable scope before deploying a method there.
For a step-by-step practical guide for pharmacy owners who want to take action in this area: Setting the Right Price in a Pharmacy: A Guide for Pharmacy Owners on Parapharmacy Products.
What This Means in Practice for a Pharmacy Pricing Strategy
- For reimbursable services, focus on the mix, not the price: the focus is shifting toward management efficiency and compliance.
- For over-the-counter products, implement a rigorous pricing strategy: competitive analysis, differentiated margins, and consistency between brand image and price.
- When it comes to governance, never combine the two scopes in the same dashboard.
Mistakes to Avoid in Pharmacy Pricing
- Apply a system of automatic competitive price alignment to reimbursable items, even though the retail price for those items is determined by a regulated mechanism.
- Neglecting the management of the parapharmacy on the grounds that “everything is regulated in the pharmacy.”
- Combining the margin on refundable products and the margin on over-the-counter products in a single dashboard.
- Relying on an unverified or outdated regulatory provision: the regulatory framework changes regularly and should be reevaluated.
- Underinvesting in competitive analysis of the drugstore sector, in the face of pressure from specialty retailers and e-commerce.
Pricing in the pharmacy sector isn't an impossible task—it's a two-tiered process that must be treated as such. To objectively assess the margin potential within your truly actionable scope, discover our offering price diagnostic.
FAQ
The Economic Committee on Health Products (CEPS) sets or negotiates the manufacturer’s price through an agreement with the pharmaceutical company, or, failing that, by ministerial decision or decree (Art. L162-16-4 CSS). The pharmacist does not set this price.
The retail price is, with very limited exceptions, a single national price. This should be verified on a case-by-case basis with official sources, depending on the product.
Non-reimbursed medications and the entire range of over-the-counter products, with profit margins that can reach 30 to 60 percent, according to industry sources.
Growth is driven in part by high- Markup, high-cost drugs, while price cuts on reimbursable products are weighing on gross margin in the absence of offsetting factors.
Yes, focused on over-the-counter products and non-reimbursable items. For reimbursable items, the focus is shifting toward administrative efficiency and managing the product mix.
The price covers the manufacturing and distribution costs. The fee, introduced in 2016, compensates the pharmacist for their services regardless of the price of the package.
See also in this feature
- Pricing in the Retail Sector: What's Changing (and What Isn't)
- Setting the Right Price at the Pharmacy: A Guide for Pharmacy Owners on Over-the-Counter Products
- Industrial B2B Pricing in Distribution: When Prices Are Still Negotiated Line by Line
Sources: Légifrance, Art. L162-16-4 CSS · Leem · Ameli.fr · USPO, 2025 Economic Analysis.
A franchisor cannot impose a resale price: the law prohibits it from doing so; it can only recommend a price or set a maximum. A franchisee’s margin is therefore governed by a documented target, defined by network segment rather than on a store-by-store basis, and applied uniformly to all retail locations within the same segment. Three tiers are usually sufficient: aggressive pricing online, geopricing in-store, and an optimized margin for the franchisee.
Optimix merged with Maxxing in July 2025, and PricingHUB was acquired by Akeneo in June 2026. In less than a year, two of the three software providers most frequently used by French retailers underwent changes in ownership, raising the question of alternatives for their customers.
This comparison evaluates Optimix XPA, PricingHUB, Mercio, Yieldigo, and BOOPER based on what truly sets a pricing solution apart in France: native support for French regulations, pricing by store or by zone, the approval process before a price changes at the register, and roadmap independence.
A manufacturer that raises its list price does not set the price on the shelf. Between the negotiated list price and the displayed price lie the retailer, its markup, and its promotions. What is measured is the price elasticity of each product, retailer by retailer.